HW201877

HW201877
Clinical data
Drug class	15-PGDH inhibitor
Identifiers
	IUPAC name 7-[(1aS,7bR)-6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl]-2-methyl[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one;
CAS Number	2927452-83-1;
PubChem CID	169836897;
ChemSpider	133325048;
Chemical and physical data
Formula	C22H22F2N6O2
Molar mass	440.455 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N2C=CC(=CC2=NN1C)N1C[C@H]2C[C@H]2c2cc(cnc12)C(=O)N1CCC(F)(F)CC1;
	InChI InChI=1S/C22H22F2N6O2/c1-27-21(32)29-5-2-15(10-18(29)26-27)30-12-14-9-16(14)17-8-13(11-25-19(17)30)20(31)28-6-3-22(23,24)4-7-28/h2,5,8,10-11,14,16H,3-4,6-7,9,12H2,1H3/t14-,16-/m1/s1; Key:KDAKIHHOWNCOTC-GDBMZVCRSA-N;

HW201877 is a drug which acts as a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). It increases levels of prostaglandin E2 and stimulates tissue regeneration, and has been researched in animal studies for treatment of conditions such as inflammatory bowel disease and idiopathic pulmonary fibrosis.^[1]

References

^ Li Q, Zang Y, An D, Yin S, Wu H, Wang M, et al. (July 2025). "Discovery of HW201877: A Highly Potent and Orally Bioavailable Inhibitor of 15-Prostaglandin Dehydrogenase to Potentiate Tissue Repair and Regeneration". Journal of Medicinal Chemistry. 68 (13): 14099–14113. doi:10.1021/acs.jmedchem.5c01361. PMID 40568827.